Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies

Author(s): Mohammad Khalid Parvez*, Kartika Padhan

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: During the eleven months of the novel SARS-CoV-2 disease (COVID-19) outbreak in China and its global spread, there is a remarkable understanding of its epidemiology, pathobiology, and clinical management strategies. While countering a heavy toll on health and the economy, world’s regional authorities are enforcing safety guidelines and providing patient care. Currently, there is no globally approved treatment or intervention for COVID-19.

Methods: A structured online literature search for peer-reviewed articles was conducted on PubMed, Europe PMC, Google, WHO, CDC, FDA, and ClinicalTrials portals, using phrases such as COVID-19 treatment and intervention, COVID-19 drugs and COVID-19 vaccines.

Results: Analysis of the retrieved data showed that as a part of ‘Solidarity Clinical Trials’, hundreds of treatment and intervention strategies, including antiviral drugs, cytokine antagonists, convalescent plasma therapy, and vaccine candidates, have been registered worldwide. While remdesivir, the anti- Ebola virus drug, has been approved as an ‘emergency use’ drug in the USA, favipiravir, the anti-flu drug, has been recently approved in Russia. Tocilizumab and sarilumab, the cytokine (IL-6) antagonists, have entered Phase-II/III clinical trials in hospitalized COVID-19 patients. Among the leading vaccine candidates, Phase-III clinical trial results of Moderna, Pfizer and Oxford vaccines seem to be game changers for COVID19.

Conclusion: The world health authorities have strongly and quickly responded to the COVID-19 pandemic. Nonetheless, world bodies must unite in combating this health crisis by developing cost-effective drugs and vaccines and making them accessible to resource-poor countries.

Keywords: SARS-CoV-2, COVID-19, antiviral, chloroquine, remdesivir, vaccine.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 3
Year: 2021
Published on: 22 April, 2021
Page: [353 - 358]
Pages: 6
DOI: 10.2174/2666796701999201116125249

Article Metrics

PDF: 7